BDTX-4876 / Black Diamond Therap - LARVOL DELTA

Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) - "Discovery-Stage Pipeline and MAP Drug Discovery Engine: Today, Black Diamond announced that it selected a development candidate, BDTX-4876, for its FGFR program. BDTX-4876 is selective against MasterKey mutations and alterations in FGFR 2 and 3, while sparing FGFR 1 and 4."

Pipeline update • Oncology

Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment (GlobeNewswire) - "Black Diamond Therapeutics...announced that it is realigning its resources to focus on key near-term value drivers and to extend its cash runway into the third quarter of 2024, supporting the execution of important clinical and preclinical milestones....Black Diamond has discontinued the development of BDTX-189 and realigned its workforce to focus on progressing its pipeline through important upcoming milestones for BDTX-1535, BDTX-4933 and discovery efforts....Black Diamond initiated investigational new drug (IND)-enabling studies in the first quarter of 2022 and expects to submit an IND for BDTX-4933 in the first half of 2023....Black Diamond anticipates announcing a development candidate for its FGFR program in 2022 in addition to disclosing a new small molecule development candidate in 2023."

Discontinued • IND • Pipeline update • Oncology

Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) - "FGFR Program: In cell-based assays, FGFR program compounds demonstrated potent and selective inhibition of a spectrum of FGFR2/3 oncogenic mutations, while sparing FGFR1. Additionally, in cell-based assays, FGFR program compounds demonstrated improved potency against resistance mutations. In an in vivo study conducted in a UM-UC-14 (FGFR3-S249C) mouse model, FGFR program compounds demonstrated anti-tumor activity....Black Diamond anticipates an IND filing in 2022."

IND • Preclinical • Oncology